Source Count: 16 | Weighted Score: 40 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: April 12, 2026
Keywords: microbiome, gut-brain axis, dysbiosis, microbiota, HMP, fecal transplant, probiotics, 16S rRNA, short-chain fatty acids, Firmicutes, Bacteroidetes, vagus nerve, immune modulation
Category Tags: microbiome, human-biology, gut-brain, immunology, microbiology
Cross-References: ZB_2_19 — Epigenetics · X_1_01 — Medicine Overview · R_1_01 — Evolution Overview

QUICK SUMMARY

The human microbiome — the collective genome of the ~38 trillion microorganisms (bacteria, archaea, fungi, viruses) inhabiting the human body — represents a second genome interacting with host physiology in ways that are reshaping medicine, immunology, neuroscience, and evolutionary biology. The Human Microbiome Project (HMP, NIH, 2007–2016) and MetaHIT (EU, 2008–2012) established that the healthy adult gut harbors 500–1,000 bacterial species with a combined gene count of ~3.3 million unique genes (~150× the human genome). The dominant phyla are Firmicutes and Bacteroidetes (~90% of gut bacteria), with Actinobacteria, Proteobacteria, and Verrucomicrobia comprising most of the remainder. The microbiome performs functions the human genome cannot: fermentation of dietary fiber into short-chain fatty acids (SCFAs — butyrate, propionate, acetate) that nourish colonocytes and regulate immune function; synthesis of vitamins B12 and K2; metabolism of bile acids and drugs; development and training of the immune system (70–80% of immune cells reside in gut-associated lymphoid tissue); and signaling to the brain via the gut-brain axis (vagus nerve, microbial metabolites, immune mediators). Dysbiosis — a disruption of normal microbial community composition — is associated with inflammatory bowel disease, obesity, type 2 diabetes, colorectal cancer, depression, autism spectrum disorder, and autoimmune conditions. The most dramatic clinical application is fecal microbiota transplantation (FMT), which achieves ~90% cure rates for recurrent Clostridioides difficile infection — one of the highest cure rates for any antibiotic-resistant infection.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Scale and Composition of the Human Microbiome

• KEY FINDING Ron Sender, Shai Fuchs, and Ron Milo (Weizmann Institute, 2016) revised the widely cited 10:1 bacteria-to-human-cell ratio (original estimate by Thomas Luckey, 1972) to approximately 1.3:1 — ~38 trillion bacteria versus ~30 trillion human cells in a 70 kg reference man. The gut harbors the greatest density (~10¹¹ bacteria/mL colonic content), followed by skin (~10⁶/cm²), oral cavity, and respiratory tract. Metagenomic sequencing by the HMP Phase I (2012) characterized microbial communities at 18 body sites in 242 healthy adults, revealing enormous interpersonal variation: no single species was universally present, though functional metabolic pathways were remarkably conserved across individuals — different species perform the same jobs.
• Primary Source: Sender, Ron, Shai Fuchs, and Ron Milo. "Revised Estimates for the Number of Human and Bacteria Cells in the Body." Cell 164.3 (2016): 337–340. DOI: 10.1016/j.cell.2016.01.013

1.2 Gut-Brain Axis

• Evidence: Bidirectional communication between the gut microbiome and the central nervous system occurs via: (1) the vagus nerve (vagotomy abolishes many microbiome-brain effects in mice); (2) microbial metabolites (SCFAs cross the blood-brain barrier; tryptophan metabolism by gut bacteria produces serotonin precursors — ~95% of the body's serotonin is produced in the gut); (3) immune signaling (microbial-induced cytokines affect neuroinflammation); and (4) the hypothalamic-pituitary-adrenal (HPA) axis (germ-free mice show exaggerated stress responses, normalizable by Bifidobacterium colonization — Sudo et al., 2004). John Cryan and Ted Dinan (University College Cork) coined "psychobiotics" — live organisms that produce mental health benefits — and demonstrated in randomized clinical trials that specific probiotics (Lactobacillus and Bifidobacterium strains) reduce cortisol and self-reported stress in healthy humans.
• Primary Source: Cryan, John, and Ted Dinan. "Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour." Nature Reviews Neuroscience 13.10 (2012): 701–712. DOI: 10.1038/nrn3346

1.3 Fecal Microbiota Transplantation (FMT)

• KEY FINDING FMT — infusion of donor fecal microbiota into a patient's GI tract — achieves ~87–92% cure rates for recurrent Clostridioides difficile infection (rCDI) in randomized controlled trials, versus ~20–30% for vancomycin. The landmark RCT by Els van Nood et al. (NEJM, 2013) was stopped early for efficacy: 15/16 FMT patients were cured vs 4/13 on vancomycin. In November 2022, the FDA approved the first standardized FMT product: Rebyota (fecal microbiota, live-jslm, Ferring Pharmaceuticals), followed by Vowst (fecal microbiota spores, live-brpk, Seres Therapeutics, April 2023) — the first orally administered microbiota therapeutic. FMT for conditions beyond CDI (IBD, metabolic syndrome, autism) shows mixed results in trials.
• Primary Source: van Nood, Els, et al. "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile." New England Journal of Medicine 368.5 (2013): 407–415. DOI: 10.1056/NEJMoa1205037

1.4 Microbiome and Immune System Development

• Evidence: Germ-free (GF) animal studies demonstrate that the microbiome is essential for normal immune development: GF mice have underdeveloped gut-associated lymphoid tissue, reduced IgA production, impaired regulatory T-cell (Treg) populations, and increased susceptibility to infection. Sarkis Mazmanian (Caltech, 2005) showed that a single molecule — polysaccharide A (PSA) from Bacteroides fragilis — is sufficient to correct T-cell deficiency and Th1/Th2 imbalance in GF mice. The "hygiene hypothesis" (David Strachan, 1989), refined as the "old friends hypothesis" (Graham Rook, 2003), proposes that reduced microbial exposure in industrialized environments contributes to the epidemic of autoimmune and allergic diseases by depriving the developing immune system of regulatory signals.

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Microbiome and Obesity

• Evidence: Jeffrey Gordon (Washington University) demonstrated that transplanting gut microbiota from obese mice (ob/ob) into germ-free recipients caused significantly greater fat gain than transplanting from lean donors (2006), and that the obese microbiome has an elevated Firmicutes:Bacteroidetes ratio with increased capacity for energy harvest from diet. Human studies confirmed that FMT from lean donors temporarily improves insulin sensitivity in obese recipients (Anne Vrieze et al., 2012). However, the direction of causality remains debated: does dysbiosis cause obesity, or does obesity-associated diet reshape the microbiome? Most evidence supports bidirectional causation, with diet as the dominant driver of microbiome composition.

2.2 Microbiome and Cancer Immunotherapy

• Evidence: Three independent studies in 2018 (Bertrand Routy et al., Science; Vancheswaran Gopalakrishnan et al., Science; Vyara Matson et al., Science) reported that specific gut microbiome compositions (enrichment in Akkermansia muciniphila, Faecalibacterium prausnitzii, Bifidobacterium longum) predict response to checkpoint inhibitor immunotherapy (anti-PD-1) in patients with melanoma, lung cancer, and kidney cancer. FMT from responding patients into germ-free mice transferred immunotherapy sensitivity. Clinical trials of FMT + immunotherapy in melanoma patients (Davar et al., Science, 2021) showed partial or complete responses in previously non-responding patients. The mechanism likely involves microbial metabolites priming anti-tumor T-cell responses.

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Microbiome as Driver of Neurodegenerative Disease

• Evidence: Emerging evidence links gut dysbiosis to Parkinson's disease, Alzheimer's disease, and ALS. Heiko Braak proposed (2003) that α-synuclein pathology in Parkinson's begins in the enteric nervous system and propagates to the brain via the vagus nerve — supported by the observation that vagotomy reduces Parkinson's risk (~40%, Danish registry study). Gut microbiome differences between PD patients and controls are consistently reported (reduced Prevotella, increased Enterobacteriaceae). However, whether microbial changes are causative or consequential remains unresolved; the gut pathology may be an early symptom of neurodegeneration rather than its origin.

3.2 Ancestral Microbiome Loss

• Evidence: Justin Sonnenburg (Stanford) hypothesizes that the progressive loss of microbiome diversity across generations in industrialized societies ("missing microbes" — Martin Blaser, NYU) constitutes an irreversible erosion of human biological heritage. The Hadza hunter-gatherers of Tanzania harbor ~40% more microbial species than Westerners, including taxa absent from all industrialized populations. Fiber-depleted diets cause microbial species loss that is not fully recoverable even with fiber reintroduction (mouse published findings demonstrate intergenerational extinction). If confirmed, this suggests an accelerating loss of evolved host-microbe partnerships that may contribute to the rising prevalence of chronic inflammatory diseases.

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Commercial Probiotics Cure Disease

• DEBUNKED The vast majority of commercial probiotic supplements have not been tested in adequate clinical trials for specific disease endpoints. Regulatory frameworks (DSHEA in the US) allow sale without efficacy evidence. Eran Elinav and Eran Segal (Weizmann Institute, 2018) demonstrated that commercial probiotics colonize the gut in only ~50% of recipients (the rest are "resisters" whose existing microbiome prevents engraftment) and that post-antibiotic probiotic use actually delayed microbiome recovery compared to spontaneous reconstitution. Specific probiotic strains have demonstrated efficacy for specific conditions (VSL#3 for pouchitis, Saccharomyces boulardii for antibiotic-associated diarrhea), but blanket health claims for generic probiotics are unsupported.

Counter-Arguments & Criticisms

Microbiome science faces a "correlation epidemic": thousands of association studies link dysbiosis to diseases without establishing causation. The gut microbiome varies with diet, geography, medication, and genetics, making it difficult to define "normal" or "healthy." Most human microbiome studies are cross-sectional (snapshots) rather than longitudinal (tracking changes over time), limiting causal inference. Animal models (germ-free mice) provide causal evidence but may not translate to humans — mouse and human microbiomes share only ~4% of species. Jack Gilbert and others have called for methodological rigor: standardized sampling, sequencing, and analytical methods; pre-registered hypotheses; and therapeutic trials as the ultimate arbiter. The commercial microbiome industry (testing kits, personalized probiotics, microbiome "coaching") has outpaced the science, marketing interventions with limited evidence.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Sender, Ron, Shai Fuchs; Ron Milo | 2016 | "Revised Estimates for the Number of Human and Bacteria Cells in the Body" | Cell | ∅ | 164.3::337–340 | ∅ | ∅ | doi:10.1016/j.cell.2016.01.013 | ∅ | ∅ | ∅
2. Human Microbiome Project Consortium | 2012 | "Structure, function and diversity of the healthy human microbiome" | Nature | ∅ | 486.7402::207–214 | ∅ | ∅ | doi:10.1038/nature11234 | ∅ | ∅ | ∅
3. Cryan, John; Ted Dinan | 2012 | "Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour" | Nature Reviews Neuroscience | ∅ | 13.10::701–712 | ∅ | ∅ | doi:10.1038/nrn3346 | ∅ | ∅ | ∅
4. van Nood, Els, et al | 2013 | "Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile" | New England Journal of Medicine | ∅ | 368.5::407–415 | ∅ | ∅ | doi:10.1056/NEJMoa1205037 | ∅ | ∅ | ∅
5. Turnbaugh, Peter, et al | 2006 | "An obesity-associated gut microbiome with increased capacity for energy harvest" | Nature | ∅ | 444.7122::1027–1031 | ∅ | ∅ | doi:10.1038/nature05414 | ∅ | ∅ | ∅
6. Routy, Bertrand, et al | 2018 | "Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors" | Science | ∅ | 359.6371::91–97 | ∅ | ∅ | doi:10.1126/science.aan3706 | ∅ | ∅ | ∅
7. Mazmanian, Sarkis, et al | 2005 | "An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system" | Cell | ∅ | 122.1::107–118 | ∅ | ∅ | doi:10.1016/j.cell.2005.05.007 | ∅ | ∅ | ∅
8. Sonnenburg, Justin; Erica Sonnenburg | 2015 | ∅ | The Good Gut: Taking Control of Your Weight, Your Mood, and Your Long-Term Health | ∅ | ∅ | New York: Penguin | ∅ | isbn:9780593074305 | ∅ | ∅ | ∅
9. Blaser, Martin | 2014 | ∅ | Missing Microbes: How the Overuse of Antibiotics Is Fueling Our Modern Plagues | ∅ | ∅ | New York: Henry Holt | ∅ | isbn:9780805098105 | ∅ | ∅ | ∅
10. Zmora, Niv, et al | 2018 | "Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features" | Cell | ∅ | 174.6::1388–1405 | ∅ | ∅ | doi:10.1016/j.cell.2018.08.041 | ∅ | ∅ | ∅
11. Davar, Diwakar, et al | 2021 | "Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients" | Science | ∅ | 371.6529::595–602 | ∅ | ∅ | doi:10.1126/science.abf3363 | ∅ | ∅ | ∅
12. Braak, Heiko, et al. | 2003 | "Staging of brain pathology related to sporadic Parkinson's disease" | Neurobiology of Aging | ∅ | 24.2::197–211 | ∅ | ∅ | doi:10.1016/S0197-4580(02)00065-9 | ∅ | ∅ | ∅
13. Sonnenburg, Erica, et al | 2016 | "Diet-induced extinctions in the gut microbiota compound over generations" | Nature | ∅ | 529.7585::212–215 | ∅ | ∅ | doi:10.1038/nature16504 | ∅ | ∅ | ∅
14. Qin, Junjie, et al | 2010 | "A human gut microbial gene catalogue established by metagenomic sequencing" | Nature | ∅ | 464.7285::59–65 | ∅ | ∅ | doi:10.1038/nature08821 | ∅ | ∅ | ∅
15. Gilbert, Jack, et al | 2018 | "Current understanding of the human microbiome" | Nature Medicine | ∅ | 24.4::392–400 | ∅ | ∅ | doi:10.1038/nm.4517 | ∅ | ∅ | ∅
16. Lynch, Susan; Oluf Pedersen | 2016 | "The Human Intestinal Microbiome in Health and Disease" | New England Journal of Medicine | ∅ | 375.24::2369–2379 | ∅ | ∅ | doi:10.1056/NEJMra1600266 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: April 12, 2026

Corrections

• 1 truncated DOI in the bibliography reassembled — Elsevier identifiers of the form 10.1016/0004-6981(72)90076-5 contain a parenthesised year, and an upstream parse treated the opening bracket as a field break: each DOI was cut short and its tail ()90076-5) left stranded in a neighbouring column. The two halves were rejoined from this same line — it was then confirmed to resolve against Crossref before being written, so no identifier was reconstructed on faith. Repaired: 10.1016/S0197-4580(02)00065-9. Corpus hygiene campaign, Phase 4, 2026-07-29.

• The Good Gut: Taking Control of Your Weight, Your Mood, and — ISBN corrected from 9780143128087 to 9780593074305, verified against Open Library (The Good Gut, Justin Sonnenburg, Erica Sonnenburg). The previous number failed its check digit.